^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PD-L1 inhibitor

    Related drugs:
    24h
    SPRINT 2: The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2 (clinicaltrials.gov)
    P2, N=52, Not yet recruiting, Montefiore Medical Center | Trial completion date: Oct 2028 --> Feb 2029 | Initiation date: May 2026 --> Sep 2026 | Trial primary completion date: Dec 2027 --> Apr 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)
    24h
    DUO-O: Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients (clinicaltrials.gov)
    P3, N=1407, Active, not recruiting, AstraZeneca | Trial completion date: Mar 2028 --> Dec 2026
    Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel
    24h
    PrE0512: Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=430, Not yet recruiting, PrECOG, LLC.
    New P3 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    Imfinzi (durvalumab) • Imdelltra (tarlatamab-dlle)
    1d
    Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) (clinicaltrials.gov)
    P2, N=54, Completed, Hospices Civils de Lyon | Unknown status --> Completed | Trial completion date: Oct 2023 --> Jun 2026 | Trial primary completion date: Oct 2023 --> Jun 2026
    Trial completion • Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • ipatasertib (RG7440)
    1d
    Targeted immunotherapy and tumor immunogenicity in liver transplant recipients: A study on lenvatinib and PD-L1 inhibition. (PubMed, Pak J Pharm Sci)
    This combination shows promising effects and good safety in patients with HCC who have received liver transplants. Such a method offers a fresh choice for treating those who are thought not to be suitable for immunotherapy, so it needs to be tested in more extensive controlled research.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
    |
    Tecentriq (atezolizumab) • sorafenib • Lenvima (lenvatinib)
    1d
    Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P1/2, N=20, Recruiting, West China Hospital
    New P1/2 trial
    |
    Lenvima (lenvatinib) • Enweida (envafolimab)
    2d
    RTOG 1308: Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer (clinicaltrials.gov)
    P3, N=330, Active, not recruiting, Radiation Therapy Oncology Group | Trial completion date: Jan 2025 --> Nov 2028 | Trial primary completion date: Jan 2025 --> Nov 2028 | Completed --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • etoposide IV
    2d
    A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM (clinicaltrials.gov)
    P2, N=31, Completed, Biotheus Inc. | Recruiting --> Completed | N=55 --> 31 | Trial completion date: Jun 2026 --> Mar 2026 | Trial primary completion date: Jun 2026 --> Mar 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • pemetrexed • pumitamig (BNT327)
    2d
    Autopsy-Proven Immune-Mediated Hepatitis With Rapid Liver Atrophy Despite Minimal Aminotransferase Elevation After Durvalumab Plus Tremelimumab Therapy for Hepatocellular Carcinoma: A Case Report. (PubMed, Clin Case Rep)
    The tumor burden was small without metastasis. This case highlights that ICI hepatitis can progress with minimal aminotransferase elevation in advanced cirrhosis, warranting multidimensional monitoring beyond aspartate aminotransferase/alanine aminotransferase, including bilirubin, coagulation parameters, clinical decompensation, and quantitative imaging.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    2d
    Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapy. (PubMed, Clin Cancer Res)
    Sequential VCN-01 plus durvalumab was better tolerated than concomitant treatment. The recommended VCN-01 phase 2 dose (RP2D) was 1.0E13 vp, on the sequential schedule. Encouraging survival was observed in patients after progressing on anti-PD-(L)1 agents. Data supports VCN-01 replication associated with increased PD-1, PD-L1, and CD8 tumor expression. Sequential systemic delivery of VCN-01 and anti-PD-L1 therapy may represent an improved treatment for HNSCC.
    P1 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    Imfinzi (durvalumab) • zabilugene almadenorepvec (VCN-01)
    2d
    First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies. (PubMed, J Immunother Cancer)
    Alomfilimab treatment was associated with an acceptable safety profile across both mono and combination approaches, accompanied by decreased ICOS+Tregs populations and enhanced CD4+ and CD8+ effector T cells cell activity. Limited clinical activity was observed despite evidence of biological activity.
    P1 data • Journal • PD(L)-1 Biomarker • IO biomarker • First-in-human
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule)
    |
    Tecentriq (atezolizumab) • alomfilimab (SAR445256)
    2d
    First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial. (PubMed, Nat Cancer)
    Durvalumab plus T-DXd demonstrated clinically relevant efficacy for first-line treatment of metastatic HR-negative, HER2-low breast cancer, with no unexpected toxicities observed. ClinicalTrials.gov identifier: NCT03742102 .
    P1/2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR negative
    |
    Imfinzi (durvalumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)